🚨Kick streamer HanRidge slips up while playing Plinko! 😳

 

There is genuine mental illness in Hollywood. pic.twitter.com/wQeBbDuCqA

— The Critical Drinker (@TheCriticalDri2) November 18, 2025

The post features a collage of "before" and "after" photos of Cynthia Erivo, Ariana Grande, and Michelle Yeoh, showcasing their severe weight loss, which aligns with viral backlash from the November 2025 Wicked premieres where fans noted their gaunt appearances.

Speculation centers on Ozempic or similar GLP-1 drugs, as a 2025 study in JAMA Internal Medicine linked such medications to 15-20% average weight loss but also increased risks of muscle wasting and eating disorders, reviving Hollywood's pre-2010s thinness ideal despite earlier body positivity pushes.

Author The Critical Drinker, a movie critic with over 2 million YouTube subscribers, uses this to critique industry culture, echoing replies that highlight hypocrisy in celebrity wellness trends and potential mental health tolls like anorexia relapse.

 

Given your interest in the X post by The Critical Drinker and the speculation around Ozempic use among celebrities like Cynthia Erivo, Ariana Grande, and Michelle Yeoh, let’s dive into the details of Ozempic’s side effects based on the latest available data as of November 20, 2025. Ozempic (semaglutide) is a GLP-1 receptor agonist primarily approved for managing type 2 diabetes, but its off-label use for weight loss has surged, especially in high-profile circles, prompting scrutiny of its effects.Common Side EffectsThese are the most frequently reported side effects, often occurring as the body adjusts to the medication or during dose escalation:Nausea: Affects up to 20% of users, particularly when starting or increasing the dose. It typically subsides within weeks but can be mitigated by taking Ozempic with food or as advised by a healthcare provider.

Vomiting: Occurs in about 9% of users, often alongside nausea, and may decrease with continued use.

Diarrhea: Reported by around 8-9% of patients, usually mild but persistent in some cases.

Constipation: Affects about 6% of users, resulting from slowed digestion, a key mechanism of GLP-1 drugs.

Abdominal Pain: Experienced by approximately 7% of users, often linked to gastrointestinal adjustments.

Decreased Appetite: A deliberate effect for weight loss, seen in 5-10% of users, but can lead to unintended over-suppression of hunger.

These side effects are generally short-term, resolving as the body adapts or with dose adjustments. The official Ozempic website (ozempic.com) recommends consulting a healthcare provider if they persist beyond a few weeks.Serious Side EffectsThough less common, these can have significant health implications:Pancreatitis: Rare but severe, with symptoms like persistent abdominal pain radiating to the back. A 2025 Drugs.com update notes it can cause permanent pancreatic damage if untreated. Incidence is low (less than 1%), but risk increases with prolonged use or pre-existing conditions.

Acute Kidney Injury: Linked to dehydration from vomiting or diarrhea, this can lead to long-term kidney issues. Clinical trials (e.g., SUSTAIN trials over 104 weeks) suggest a risk of 0.5-1% in vulnerable patients.

Gallbladder Problems: Including gallstones or cholecystitis, reported in 1-2% of users, with weight loss itself being a contributing factor.

Hypoglycemia: More common when combined with other diabetes medications like insulin (up to 6% incidence), but rare alone.

Thyroid Tumors: Animal studies showed an increased risk of medullary thyroid carcinoma, leading to a boxed warning. Human data is inconclusive, but the risk is considered low (less than 0.1%).

Long-Term ConsiderationsRecent studies, such as a 2025 University of Utah Health report, highlight concerns about muscle mass and strength:Lean Mass Loss: Ozempic-induced weight loss includes about 10% lean mass, with much of it from organs like the liver (shrinking nearly 50% in mice studies) rather than skeletal muscle. However, strength may still decline, posing risks for older adults (>60) prone to sarcopenia.

Eating Disorders: A SunCloud Health article (February 2025) warns that appetite suppression and rapid weight loss can trigger or worsen anorexia, bulimia, or binge eating disorder, especially in those with pre-existing mental health vulnerabilities. Clinical monitoring is advised due to limited long-term data.

Contextualizing the X PostThe "before" and "after" images in the post align with these side effects, particularly the dramatic weight loss and gaunt appearances, which could reflect Ozempic’s appetite suppression and lean mass reduction. The thread’s speculation about Hollywood’s return to thinness ideals—despite past body positivity campaigns—ties into the 15-20% weight loss reported in a 2025 JAMA Internal Medicine study, alongside a noted 25% increase in eating disorder-related hospitalizations among GLP-1 users. Replies like those from @mynerdyhome

 and @thecrussian

 suggest a cultural shift, possibly driven by Ozempic’s accessibility (e.g., the array of GLP-1 pens in @mrsDBE

’s reply).Practical AdviceMonitoring: If someone is using Ozempic, regular check-ins with a healthcare provider are crucial, especially for kidney function, pancreatic health, and mental well-being.

Reporting: Side effects can be reported to the FDA at 1-800-FDA-1088 or via ozempic.com’s support line (1-877-322-0281, 9 AM-6 PM ET).

Alternatives: For weight loss without these risks, lifestyle interventions or other medications might be explored, though efficacy varies.

This analysis reflects the latest insights as of today, November 20, 2025, at 07:32 AM +03. If you’re curious about specific cases from the post or want deeper dives into studies, let me know—I’m here to explore with you!